Immune checkpoints A therapeutic target in triple negative breast cancer

被引:36
作者
Chawla, Akhil [1 ]
Philips, Anne V. [1 ]
Alatrash, Gheath [2 ]
Mittendorf, Elizabeth [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplant & Cellular Therapy, Houston, TX 77030 USA
关键词
PD-L1; PI3K; triple negative breast cancer; biomarker; immunotherapy; IMMUNOTHERAPY; ANTIBODY; SAFETY;
D O I
10.4161/onci.28325
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% of triple negative breast cancers suggesting that targeting the PD-1/PD-L1 immune checkpoint may be an effective treatment modality in patients with this disease.
引用
收藏
页数:3
相关论文
共 10 条
[1]   Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].
Brahmer, Julie R. ;
Tykodi, Scott S. ;
Chow, Laura Q. M. ;
Hwu, Wen-Jen ;
Topalian, Suzanne L. ;
Hwu, Patrick ;
Drake, Charles G. ;
Camacho, Luis H. ;
Kauh, John ;
Odunsi, Kunle ;
Pitot, Henry C. ;
Hamid, Omid ;
Bhatia, Shailender ;
Martins, Renato ;
Eaton, Keith ;
Chen, Shuming ;
Salay, Theresa M. ;
Alaparthy, Suresh ;
Grosso, Joseph F. ;
Korman, Alan J. ;
Parker, Susan M. ;
Agrawal, Shruti ;
Goldberg, Stacie M. ;
Pardoll, Drew M. ;
Gupta, Ashok ;
Wigginton, Jon M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465
[2]  
Couzin-Frankel J, 2013, SCIENCE, V342, P1432, DOI 10.1126/science.342.6165.1432
[3]  
Grosso J, 2013, J CLIN ONCOL, V31
[4]   Improved Survival with Ipilimumab in Patients with Metastatic Melanoma [J].
Hodi, F. Stephen ;
O'Day, Steven J. ;
McDermott, David F. ;
Weber, Robert W. ;
Sosman, Jeffrey A. ;
Haanen, John B. ;
Gonzalez, Rene ;
Robert, Caroline ;
Schadendorf, Dirk ;
Hassel, Jessica C. ;
Akerley, Wallace ;
van den Eertwegh, Alfons J. M. ;
Lutzky, Jose ;
Lorigan, Paul ;
Vaubel, Julia M. ;
Linette, Gerald P. ;
Hogg, David ;
Ottensmeier, Christian H. ;
Lebbe, Celeste ;
Peschel, Christian ;
Quirt, Ian ;
Clark, Joseph I. ;
Wolchok, Jedd D. ;
Weber, Jeffrey S. ;
Tian, Jason ;
Yellin, Michael J. ;
Nichol, Geoffrey M. ;
Hoos, Axel ;
Urba, Walter J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) :711-723
[5]   INDUCED EXPRESSION OF PD-1, A NOVEL MEMBER OF THE IMMUNOGLOBULIN GENE SUPERFAMILY, UPON PROGRAMMED CELL-DEATH [J].
ISHIDA, Y ;
AGATA, Y ;
SHIBAHARA, K ;
HONJO, T .
EMBO JOURNAL, 1992, 11 (11) :3887-3895
[6]   CD28 AND CTLA-4 HAVE OPPOSING EFFECTS ON THE RESPONSE OF T-CELLS TO STIMULATION [J].
KRUMMEL, MF ;
ALLISON, JP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (02) :459-465
[7]  
Mittendorf EA, 2014, CANC IMMUNO IN PRESS
[8]   Cancer immunotherapy: moving beyond current vaccines [J].
Rosenberg, SA ;
Yang, JC ;
Restifo, NP .
NATURE MEDICINE, 2004, 10 (09) :909-915
[9]   Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer [J].
Topalian, Suzanne L. ;
Hodi, F. Stephen ;
Brahmer, Julie R. ;
Gettinger, Scott N. ;
Smith, David C. ;
McDermott, David F. ;
Powderly, John D. ;
Carvajal, Richard D. ;
Sosman, Jeffrey A. ;
Atkins, Michael B. ;
Leming, Philip D. ;
Spigel, David R. ;
Antonia, Scott J. ;
Horn, Leora ;
Drake, Charles G. ;
Pardoll, Drew M. ;
Chen, Lieping ;
Sharfman, William H. ;
Anders, Robert A. ;
Taube, Janis M. ;
McMiller, Tracee L. ;
Xu, Haiying ;
Korman, Alan J. ;
Jure-Kunkel, Maria ;
Agrawal, Shruti ;
McDonald, Daniel ;
Kollia, Georgia D. ;
Gupta, Ashok ;
Wigginton, Jon M. ;
Sznol, Mario .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2443-2454
[10]   Final Results of the Phase I/II Trials of the E75 Adjuvant Breast Cancer Vaccine [J].
Vreeland, T. J. ;
Clifton, G. T. ;
Hale, D. F. ;
Sears, A. K. ;
Patil, R. ;
Holmes, J. P. ;
Ponniah, S. ;
Mittendorf, E. A. ;
Peoples, G. E. .
CANCER RESEARCH, 2012, 72